Texas House Bill Addresses Medicaid MCO Bias Against 340B Pharmacies

Texas state capitol building with United States and Texas state flags
A bill in Texas would stop Medicaid MCOs and their PBMs from paying less than what Texas Medicaid pays for 340B-obtained drugs.

A bill has been introduced in Texas to stop Medicaid managed care organizations and their pharmacy benefit managers from reimbursing pharmacies for 340B-acquired drugs at less than what Texas Medicaid pays for the same 340B drugs.

Texas House Bill 1293

Read More »

PhRMA Discusses Joint 340B Reform Deal with Health Centers in Interview; Hospital Groups Denounce Plan

Nicole Longo headshot
“There is no way for 340B to be fixed without everybody coming to the table,” PhRMA spokesperson Nicole Longo said in an interview with 340B Report.

The fallout continues from drug makers and health centers’ decision to work together to change the 340B program, with the drug industry giving its first interview about the deal to 340B Report on Friday and several hospital groups jointly blasting

Read More »

Connecticut Governor’s First of Its Kind Three-Pronged 340B Bill Passes Hurdle in Legislature

Connecticut House of Representatives chamber
The Connecticut House might vote soon on a bill to require hospital reporting on 340B revenue, prohibit drug maker restrictions on 340B contract pharmacy use, and prohibit pharmacy benefit manager discrimination against 340B entities and pharmacies.

Connecticut Gov. Ned Lamont’s novel bill to require hospital reporting on 340B revenue, prohibit drug maker restrictions on 340B contract pharmacy use, and prohibit pharmacy benefit manager discrimination against 340B entities and pharmacies has passed its first test in the

Read More »

How to Make the Most Out of the 340B Coalition Conference

Headed to the 340B Coalition Winter Conference? Here’s how to get the most bang for your buck and walk away with ideas and contacts that will impact your mission. (155)

SPONSORED CONTENT

It’s that time again: The 340B Coalition Winter Conference, known as the can’t-miss gathering of covered entities, health care providers, pharmacy and pharmacy service providers, drug manufacturers, government agencies, and other organizations dedicated to driving health equity for underserved populations via the 340B drug discount program, is just around the corner.

Over the course of three days, the event draws thousands of industry insiders, features a full program of educational, networking, and demo sessions, and showcases approximately 70 exhibitors. But with so much on the agenda—during a critical year for insights and collaboration into the changing 340B world—how can attendees get the most bang for their collective bucks?

Find out below as Avita Care Solutions leaders (and veteran 340B Coalition Conference-goers) Michael Yount and Lee Horner weigh in with tips on using the event to find thought leaders and make lasting partnerships. And don’t

Read More »

340B Registration for Second Quarter of 2023 Begins April 1, with COVID Public Health Emergency Set to Expire in May

Q2 340B registration
Q2 2023 registration for the 340B program starts April 1 and is expected to end April 17.

The second quarterly period this year for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin Saturday, April 1, and is expected to end on Monday, April 17.

Normally, a quarterly 340B registration period runs from

Read More »

News Alert

Amgen Expands 340B Contract Pharmacy Limits

Amgen wordmark on building
Amgen today announced a major expansion of its conditions on 340B pricing when hospitals use contract pharmacies.

Biopharmaceutical manufacturer Amgen this afternoon significantly expanded its conditions on 340B pricing when hospitals use contract pharmacies.

Johnson & Johnson announced a similar expansion of its 340B contract pharmacy limits last month. Hospital groups slammed J&J’s new restrictions.

Amgen’s

Read More »

U.S. House Subcommittee Could Discuss 340B on Two Consecutive Days This Month

House Committee on E&C wall plaque
The House Energy & Commerce Health Subcommittee will review a draft drug shortages bill with 340B program implications.

U.S. House Republicans yesterday asked Department of Health and Human Services Secretary Xavier Becerra to testify March 29 about the Biden administration’s health care budget request.

Becerra will appear before the Energy & Commerce health subcommittee the day after it

Read More »

MedPAC’s Call to Replace Medicare DSH Formula Could Spill Over into 340B

MedPAC report to the Congress title page
MedPAC this week recommended replacing the Medicare DSH patient adjustment percentage for Medicare hospital payment purposes. The 340B program uses the same calculation as one of its hospital eligibility criteria.

Congressional Medicare advisers yesterday formally recommended replacing the formula Medicare uses to distribute extra payments to safety net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.

The 340B program uses the same calculation—the Medicare disproportionate share adjustment percentage—to determine eligibility

Read More »

CMS Announces First Drugs Subject to Medicare Inflation Rebates, Issues Guidance Addressing 340B and Medicare Negotiated Drug Prices

CMS building
CMS said planned Medicare Part B premium increases are partly the result of the proposed lump sum payment for previous illegal 340B hospital cuts.

The U.S. Centers for Medicare & Medicaid Services Tuesday announced the first 27 prescription drugs that will be subject to Medicare Part B inflation rebates, a list that includes AbbVie’s blockbuster arthritis drug Humira, which generated $5.6 billion in global

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report